bpc 157 safety concerns fda warning bpc-157 peptide not approved to discuss easing restrictions on peptides despite The Dangers of BPC-157: FDA

BPC 157 was studied almost exclusively by the same Croatian team that created it, doing rat study after rat study, while MK-677 was the domain of the Merck Research Laboratories in New Jersey, whose scientists conducted multiple small trials in humans in the 1990s, trying to see if the drug had interesting effects on a variety of surrogate markers

A typical transitional protocol might involve four weeks at 0.25 mg daily, followed by two weeks at 0.15 mg daily, then maintenance at 0.1 mg daily for extended periods

Why Some People Cant Convert B12 Effectively Up to 4050% of the population carries genetic polymorphisms (MTHFR C677T, A1298C) that impair their ability to convert B12 effectively

Table 1 Summary of the clinical trials to test the effect of Zn Supplementation on IBD